HoldingsChannel.com
| Date | Insider | Price | Amount |
|---|---|---|---|
| 4-10-2024 Insider Buy |
Jonathan Finn |
$1.77 CAGR » |
$44,250.00 25,000 shares |
| 11-15-2017 Insider Buy |
Kyle Guse CFO, Gen Counsel and Secretary |
$0.34 CAGR » |
$3,369.30 10,000 shares |
| 4-17-2017 Insider Buy |
H. Lawrence Remmel Director |
$0.63 CAGR » |
$1,580.00 2,500 shares |
| 4-1-2016 Insider Buy |
H. Lawrence Remmel Director |
$0.33 CAGR » |
$495.00 1,500 shares |
| 3-9-2016 Insider Buy |
Steven C. Quay President & CEO |
$0.37 CAGR » |
$5,550.00 15,000 shares |
| 3-9-2016 Insider Buy |
Shu-chih Chen Director and >10% Owner |
$0.37 CAGR » |
$5,550.00 15,000 shares |
| 2-16-2016 Insider Buy |
Shu-chih Chen Director and >10% Owner |
$0.53 CAGR » |
$7,950.00 15,000 shares |
| 2-16-2016 Insider Buy |
Steven C. Quay President & CEO |
$0.53 CAGR » |
$7,950.00 15,000 shares |
| 1-19-2016 Insider Buy |
Steven C. Quay President & CEO |
$0.20 CAGR » |
$10,000.00 50,000 shares |
| 1-19-2016 Insider Buy |
Shu-chih Chen Director and >10% Owner |
$0.20 CAGR » |
$10,000.00 50,000 shares |
| 6-12-2015 Insider Buy |
H. Lawrence Remmel Director |
$1.30 CAGR » |
$7,020.00 5,400 shares |
| 11-21-2013 Insider Buy |
Gregory L. Weaver Director |
$2.58 CAGR » |
$25,785.00 10,000 shares |
| 5-15-2013 Insider Buy |
Alexander D. Cross Director |
$5.49 CAGR » |
$2,744.95 500 shares |
| 1-8-2013 Insider Buy |
H. Lawrence Remmel Director |
$4.12 CAGR » |
$16,460.00 4,000 shares |
Also See: Institutional Holders of ATOS
Also See: SEC filings
|
Growth of $10,000.00 Without Dividends Reinvested |
||
| Start date: | 04/11/2024 | |
| End date: | 05/03/2024 | |
| Start price/share: | $1.77 | |
| End price/share: | $1.66 | |
| Dividends collected/share: | $0.00 | |
| Total return: | -6.21% | |
| Annualized Gain: | -103.11% | |
| Starting investment: | $10,000.00 | |
| Ending investment: | $9,379.00 | |
| Years: | 0.06 | |
Atossa Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Atossa Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding ATOS
 Free ATOS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
|
|
|
Other companies seeing insider buying close in time to when the Atossa Therapeutics Insider Buying occurred are:
Dominari Holdings Insider Buying
|
